Added to YB: 2026-09-17
Pitch date: 2026-09-15
NUVB [neutral]
Nuvation Bio Inc.
Author Info
No bio for this author
Company Info
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Market Cap
$2.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.80
P/E
-13.54
EV/Sales
10.84
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 1: Nuvation Bio Inc.
NUVB (quick overview): Nuvation Bio pairs commercial ROS1-positive lung-cancer drug Eptrosy with potentially larger upside from Safusidenib in IDH1-mutant glioma. Management cites Eptrosy’s 90% response rate and response duration exceeding four years, with adoption hinging on better molecular testing and physician education. The key uncertainty is whether Safusidenib’s promising early response and durability data can produce regulatory-relevant evidence well before the 2029 Sigma pivotal PFS readout.
Read full article (1 min)